Improved outcomes in stroke thrombolysis with pre-specified imaging criteria

Canadian Journal of Neurological Sciences

Volumn 28, Issue 2, 2001, Pages 113-119

  Silver, B ^a   Demaerschalk, B ^a   Merino, J G ^a   Wong, E ^a   Tamayo, A ^a   Devasenapathy, A ^a   O'Callaghan, C ^a   Kertesz, A ^a   Young, G B ^a   Fox, A J ^a   Spence, J D ^a   Hachinski, V ^a  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MORTALITY; PRIORITY JOURNAL; STROKE; TREATMENT OUTCOME;

EID: 0035007970     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S031716710005277X     Document Type: Article

References (29)

1. Tissue plasminogen activator for acute ischemic stroke
2. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)
3. Intravenous tissue-type plasminogen activator for treatment of acute stroke: The Standard Treatment with Alteplase to Reverse Stroke (STARS) study
4. Effectiveness of tPA in acute ischemic stroke: Outcome relates to appropriateness
5. Intravenous tissue plasminogen activator for acute ischemic stroke: Feasibility, safety, and efficacy in the first year of clinical practice
6. Early intravenous thrombolysis for acute ischemic stroke in a community-based approach
7. Use of tissue-type plasminogen activator for acute ischemic stroke: The Cleveland area experience
8. Acute stroke: Usefulness of early CT findings before thrombolytic therapy
9. The Canadian Activase for Stroke Effectiveness Study (CASES)
10. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: A randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke
11. "Disappearing infarcts": Signs of apparently reversible ischemic changes on serial CT and MR scans
12. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: A randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism
13. If nothing goes wrong, is everything all right? Interpreting zero numerators
14. Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: A multicenter survey. The t-PA Stroke Survey Group
15. Intravenous tissue plasminogen activator for acute ischemic stroke: A Canadian hospital's experience
16. Treating acute stroke patients with intravenous tPA. The OSF stroke network experience
17. Neurologists' attitudes regarding rt-PA for acute ischemic stroke
18. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators
19. Thrombolytic therapy with streptokinase in acute ischemic stroke. The Multicenter Acute Stroke Trial - Europe Study Group
20. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group
21. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice
22. An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus
23. Tissue plasminogen activator does not increase neuronal damage in rat models of global and focal ischemia
24. Effects of tissue type plasminogen activator in embolic versus mechanical models of focal cerebral ischemia in rats
25. Agreement and variability in the interpretation of early CT changes in stroke patients qualifying for intravenous rtPA therapy
26. Results from the first year of the New Zealand cot death study
27. New Zealand's SIDS prevention program and reduction in infant mortality